Heghine Khachatryan on VWD: A Landmark in the History of Hematology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, sreposted from Haematologica Journal on LinkedIn:
”A Landmark in the History of Hematology
One hundred years ago, the Finnish physician Erik Adolf von Willebrand published his seminal description of hereditary pseudohemophilia, a disorder that would later bear his name as von Willebrand disease.
This groundbreaking work was the first to clearly demonstrate that:
• inherited bleeding disorders may affect both sexes,
• the clinical phenotype can differ fundamentally from classical hemophilia, and
• family-based observation and pedigree analysis are critical to understanding disorders of hemostasis.
-The original genealogical diagram, shown here, represents more than a historical artifact—it laid the scientific foundation for modern concepts of primary hemostasis, platelet–vessel wall interaction, and the role of von Willebrand factor in coagulation.
-A century later, von Willebrand’s observations continue to inform contemporary diagnostics, molecular genetics, and individualized therapeutic strategies in bleeding disorders.
This milestone reminds us that careful clinical observation remains the cornerstone of scientific progress, even in the era of advanced genomics and precision medicine.”
Quoting Haematologica Journal‘s post:
”Landmark paper in Hematology: One hundred years ago the Finnish physician Erik Adolf von Willebrand published his landmark paper on hereditary pseudohemophilia in Documents of the Finnish Society of Medicine: he had discovered the disease that nowadays we universally known by his name.”
Read the full article here.
Article: The landmark contribution by Erik von Willebrand
Authors: Riitta Lassila, Erik Berntorp
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026